Goldcoast Resource Corp. (GCR.CX)
0.82
+0.02
(+2.50%)
CAD |
CNSX |
Aug 25, 16:00
Goldcoast Resource EPS Diluted (Quarterly) : -0.0725 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -0.0725 |
| December 31, 2025 | -0.0303 |
| September 30, 2025 | -0.0312 |
| June 30, 2025 | -6.018 |
| March 31, 2025 | -0.503 |
| December 31, 2024 | -0.4195 |
| September 30, 2024 | 0.5499 |
| June 30, 2024 | 0.0741 |
| March 31, 2024 | -52.48 |
| December 31, 2023 | 0.2765 |
| September 30, 2023 | -0.385 |
| June 30, 2023 | -1.836 |
| March 31, 2023 | -3.113 |
| December 31, 2022 | -1.349 |
| September 30, 2022 | -1.229 |
| June 30, 2022 | -1.439 |
| March 31, 2022 | -1.303 |
| December 31, 2021 | -1.500 |
| September 30, 2021 | -1.338 |
| June 30, 2021 | -1.472 |
| December 31, 2020 | -4.577 |
| September 30, 2020 | -0.4818 |
| June 30, 2020 | -0.4618 |
| March 31, 2020 | -0.2811 |
| December 31, 2019 | -0.4216 |
| Date | Value |
|---|---|
| September 30, 2019 | -0.2008 |
| June 30, 2019 | -0.3011 |
| March 31, 2019 | -0.2811 |
| December 31, 2018 | -5.782 |
| September 30, 2018 | -0.9637 |
| June 30, 2018 | -0.9637 |
| March 31, 2018 | 5.782 |
| December 31, 2017 | -0.8432 |
| September 30, 2017 | -0.9235 |
| June 30, 2017 | -1.225 |
| March 31, 2017 | -1.205 |
| December 31, 2016 | -6.645 |
| September 30, 2016 | -1.586 |
| June 30, 2016 | -2.168 |
| March 31, 2016 | -1.104 |
| December 31, 2015 | 2.108 |
| September 30, 2015 | -1.747 |
| June 30, 2015 | -2.048 |
| March 31, 2015 | -1.405 |
| December 31, 2014 | -2.369 |
| September 30, 2014 | -2.309 |
| June 30, 2014 | -4.798 |
| March 31, 2014 | -3.132 |
| December 31, 2013 | -6.344 |
| September 30, 2013 | -4.336 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Kane Biotech, Inc. | -0.0039 |
| Quest PharmaTech, Inc. | 0.0201 |
| BriaCell Therapeutics Corp. | -1.354 |
| Vaxil Bio Ltd. | -0.0269 |
| Waverley Pharma, Inc. | -0.0031 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.1629M |
| Total Expenses (Quarterly) | 0.1629M |
| Enterprise Value | 1.404M |
| Earnings Yield | -750.2% |
| Normalized Earnings Yield | -739.52 |